Cypress Capital Management (Delaware)’s AstraZeneca AZN Stock Holding History

Cypress Capital Management (Delaware)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-32,972	Closed	-$3.62M	–	16
2022 Q3	$3.62M	Sell	32,972 -525	-2%	-$66.6K	0.67%	47
2022 Q2	$4.43M	Sell	33,497 -50	-0.1%	-$6.56K	0.66%	55
2022 Q1	$4.45M	Buy	33,547 +225	+0.7%	+$27K	0.56%	58
2021 Q4	$3.88M	Buy	33,322 +27,983	+524%	+$3.29M	0.44%	62
2021 Q3	$640K	Hold	5,339	–	–	0.08%	125
2021 Q2	$640K	Buy	5,339 +2,375	+80%	+$261K	0.08%	126
2021 Q1	$295K	Buy	+2,964	New	+$298K	0.04%	154

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cypress Capital Management (Delaware)'s AZN Position: Q4 2022 in Review

Cypress Capital Management (Delaware) sold out of AstraZeneca (AZN) in Q4 2022, closing a stake of 32,972 shares — an estimated $3.62M sold.

Cypress Capital Management (Delaware) first reported a position in AZN in Q1 2021 and held it in 7 quarters. The position peaked at $4.45M in Q1 2022. 1,061 funds tracked by Wall St. Rank hold AZN as of Q4 2022.

Cypress Capital Management (Delaware) reported no remaining AstraZeneca position as of Q4 2022 after selling out during the quarter.
Cypress Capital Management (Delaware) sold 32,972 AstraZeneca shares in Q4 2022, an estimated $3.62M.
Cypress Capital Management (Delaware) first reported a position in AstraZeneca in Q1 2021 and held it in 7 quarters.
Cypress Capital Management (Delaware)'s AstraZeneca position peaked at $4.45M in Q1 2022.
1,061 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2022.

Based on Cypress Capital Management (Delaware)'s 13F filing for Q4 2022.